The renin-angiotensin-aldosterone system (RAAS) is a hormonal cascade that regulates blood pressure, fluid balance, electrolyte Homeostasis, and β far more significantly than classical physiology textbooks acknowledge β inflammation, tissue remodelling, Fibrosis, and metabolic function. The traditional view presents RAAS as a simple endocrine circuit: the kidney senses low blood pressure or low sodium, releases renin, which ultimately generates angiotensin II to raise blood pressure through vasoconstriction and Aldosterone-mediated sodium retention. While this hemodynamic function is real, it dramatically undersells the system's significance. Angiotensin II is one of the most potent pro-inflammatory molecules in the body, activating NF-ΞΊB, generating reactive oxygen species through NADPH oxidase, stimulating pro-fibrotic pathways via TGF-beta, and directly modulating immune cell function. The RAAS is not merely a blood pressure regulator β it is an immunometabolic signaling system with profound connections to chronic low-grade inflammation, insulin resistance, obesity, cardiovascular disease, and even neuroinflammation.
The discovery of a counter-regulatory arm of the RAAS β the ACE2/angiotensin 1-7/Mas receptor axis β fundamentally changed the understanding of this system from a linear cascade to a dual-axis balance. The classical arm (ACE/angiotensin II/AT1 receptor) is pro-inflammatory, pro-fibrotic, vasoconstrictive, and promotes sodium retention. The counter-regulatory arm (ACE2/angiotensin 1-7/Mas receptor) is anti-inflammatory, anti-fibrotic, vasodilatory, and promotes insulin sensitivity. Health depends on the balance between these two arms, and in virtually every chronic disease state β hypertension, metabolic syndrome, heart failure, chronic kidney disease, and chronic low-grade inflammation β this balance tips toward the pro-inflammatory classical arm. The SARS-CoV-2 pandemic brought the RAAS to global attention because the virus uses ACE2 as its cellular entry receptor, and the consequent downregulation of ACE2 removes the counter-regulatory brake, unleashing unopposed angiotensin II signaling and contributing to the inflammatory storm that characterises severe COVID-19.
For the cPNI practitioner, the RAAS represents a critical nexus where cardiovascular, metabolic, immune, and inflammatory pathways converge. Adipose tissue β particularly visceral fat β produces its own angiotensinogen, meaning that obesity directly activates the RAAS independently of blood pressure, creating a self-amplifying cycle of inflammation, insulin resistance, and further fat accumulation. Understanding the RAAS is essential for grasping why metabolic syndrome, hypertension, and chronic low-grade inflammation so consistently co-occur, and why interventions targeting adipose tissue reduction, anti-inflammatory nutrition, physical activity, and stress management can simultaneously improve blood pressure, metabolic function, and inflammatory status.
The RAAS cascade begins with angiotensinogen, a 453-amino-acid alpha-2-globulin protein produced constitutively by the liver and released into the circulation. Angiotensinogen production is upregulated by several factors including Cortisol (via glucocorticoid response elements in the angiotensinogen gene promoter), oestrogen (explaining the increase in angiotensinogen during pregnancy and with oral contraceptive use), thyroid hormone, angiotensin II itself (positive feedback), and pro-inflammatory cytokines such as IL-6 and TNF-Ξ±. This last point is critically important for cPNI: inflammation directly increases the substrate for the entire RAAS cascade, providing a molecular mechanism by which chronic inflammatory states amplify RAAS activation.
The rate-limiting enzyme of the cascade is renin, an aspartyl protease synthesised, stored, and released by the juxtaglomerular (JG) cells of the renal afferent arterioles. Renin is released in response to three primary stimuli: (1) reduced renal perfusion pressure detected by baroreceptors in the afferent arteriole (the intrinsic "pressure sensor"), (2) reduced sodium chloride delivery to the macula densa cells of the distal tubule (detected through the tubuloglomerular feedback mechanism via NKCC2 transporter and adenosine signaling), and (3) sympathetic nervous system activation acting on beta-1 adrenergic receptors on JG cells. This third mechanism provides a direct link between the sympathetic nervous system, the HPA axis (which drives sympathetic activation via CRH and noradrenaline), and the RAAS β explaining why psychological stress and chronic sympathetic overactivation elevate blood pressure through RAAS engagement. Renin cleaves angiotensinogen to produce the biologically inactive decapeptide angiotensin I (Ang I).
Angiotensin-converting enzyme (ACE, also known as kininase II) then converts the inactive angiotensin I to the active octapeptide angiotensin II (Ang II) by removing two C-terminal amino acids. ACE is a zinc-dependent metallopeptidase expressed primarily on the luminal surface of pulmonary vascular endothelium β the lungs are the primary site of angiotensin II generation because of their massive endothelial surface area. However, ACE is also expressed in the endothelium of virtually every vascular bed, as well as in the kidney, heart, brain, and adipose tissue, enabling local tissue-level angiotensin II production (the "tissue RAAS"). Importantly, ACE also degrades Bradykinin, a potent vasodilator and promoter of nitric oxide and Prostaglandins production. This dual function means that ACE activation simultaneously increases a vasoconstrictor (angiotensin II) and destroys a vasodilator (bradykinin) β a double hemodynamic hit. It also explains why ACE inhibitors, by blocking both functions, produce effects beyond what simple angiotensin II reduction would predict: the bradykinin potentiation contributes to vasodilation, cardioprotection, and β as a side effect β the dry cough that occurs in 5-20% of patients on ACE inhibitors (bradykinin accumulation stimulates C-fibres in the airway).
Angiotensin II exerts the vast majority of its classical effects through the AT1 receptor (angiotensin II type 1 receptor), a Gq/G12/13-coupled GPCR expressed on vascular smooth muscle cells, cardiomyocytes, adrenal cortical cells, renal tubular cells, neurons, adipocytes, macrophages, and many other cell types. AT1 receptor activation produces a remarkably diverse array of effects:
Hemodynamic effects: Direct vasoconstriction of arteriolar smooth muscle (the most potent endogenous vasoconstrictor), increased cardiac contractility and heart rate (through sympathetic potentiation), and increased renal sodium reabsorption in the proximal tubule.
Aldosterone secretion: Angiotensin II is the primary stimulus for Aldosterone release from the adrenal zona glomerulosa (discussed in detail below).
ADH/Vasopressin release: Angiotensin II stimulates vasopressin (ADH) release from the posterior pituitary, promoting water retention and further contributing to volume expansion and blood pressure elevation.
Sympathetic potentiation: Angiotensin II facilitates noradrenaline release from sympathetic nerve terminals (by inhibiting noradrenaline reuptake) and enhances sympathetic ganglionic transmission. This creates a positive feedback loop between the RAAS and the sympathetic nervous system that is particularly relevant in chronic stress states.
Pro-inflammatory signaling: This is the dimension most relevant to cPNI. Angiotensin II, via AT1, activates NF-ΞΊB through multiple mechanisms including reactive oxygen species (ROS) generation, IkB kinase activation, and MAPK pathway engagement. This drives transcription of pro-inflammatory Cytokines (IL-6, TNF-Ξ±, IL-1Ξ²), chemokines (MCP-1/CCL2), adhesion molecules (VCAM-1, ICAM-1), and Cyclooxygenase-2 (COX-2). Angiotensin II is therefore a direct pro-inflammatory stimulus, linking hemodynamic dysregulation to immune activation.
Oxidative stress: AT1 activation potently stimulates NADPH oxidase (NOX) enzymes, particularly NOX2 in endothelial cells, vascular smooth muscle, and macrophages. The resulting superoxide generation depletes nitric oxide (by converting it to peroxynitrite), damages endothelial function, oxidises LDL (promoting atherosclerosis), and perpetuates NF-ΞΊB activation. The angiotensin II-ROS-NF-kB axis is a central mechanism in vascular inflammation and endothelial dysfunction.
Fibrosis and tissue remodelling: Angiotensin II stimulates production of TGF-beta (transforming growth factor beta), the master pro-fibrotic cytokine. TGF-beta drives fibroblast-to-myofibroblast transition, extracellular matrix deposition (collagen, fibronectin), and epithelial-to-mesenchymal transition. This explains the organ fibrosis (cardiac, renal, hepatic, pulmonary) that accompanies chronic RAAS overactivation and why ACE inhibitors and angiotensin receptor blockers (ARBs) have anti-fibrotic effects independent of blood pressure reduction.
Thirst and sodium appetite: Angiotensin II acts on circumventricular organs (subfornical organ, OVLT) to stimulate thirst and salt appetite β a behavioural drive to increase blood volume that complements the renal effects.
The discovery of ACE2 (angiotensin-converting enzyme 2) in 2000 revealed that the RAAS is not a linear cascade but a balanced system with built-in counter-regulation. ACE2 is a carboxypeptidase that cleaves a single amino acid from angiotensin II, converting it to the heptapeptide angiotensin 1-7 (Ang 1-7). This is the "good" arm of the RAAS. Angiotensin 1-7 acts on the Mas receptor (MasR), producing effects that directly oppose those of angiotensin II via AT1: vasodilation (via nitric oxide and prostacyclin), anti-inflammatory signaling (reduced NF-kB activation, decreased cytokine production), anti-fibrotic effects (reduced TGF-beta, decreased collagen deposition), anti-proliferative effects on vascular smooth muscle, improved insulin sensitivity, and cardioprotection. ACE2 also converts angiotensin I to angiotensin 1-9, which can be further processed to Ang 1-7, providing an alternative pathway to the counter-regulatory arm.
ACE2 is expressed in the heart, kidneys, lungs (type II alveolar epithelial cells), intestinal epithelium, vascular endothelium, and testis. The balance between ACE (producing Ang II) and ACE2 (degrading Ang II to Ang 1-7) determines the local tissue angiotensin II/angiotensin 1-7 ratio, which in turn determines whether pro-inflammatory/pro-fibrotic or anti-inflammatory/anti-fibrotic signaling dominates. In chronic low-grade inflammation, obesity, hypertension, and aging, ACE2 expression tends to decrease while ACE activity increases, tipping the balance toward the pathological arm.
Aldosterone, the mineralocorticoid hormone released from the adrenal zona glomerulosa in response to angiotensin II (and to a lesser extent potassium and ACTH), acts on the mineralocorticoid receptor (MR) in the distal nephron (principal cells of the collecting duct) to increase sodium reabsorption and potassium excretion via upregulation of the epithelial sodium channel (ENaC) and Na+/K+-ATPase. This is the classical "sodium-retaining" function of aldosterone that expands blood volume and maintains blood pressure.
However, mineralocorticoid receptors are expressed far beyond the kidney β in cardiomyocytes, vascular smooth muscle, endothelial cells, adipocytes, macrophages, and the brain β and aldosterone's effects at these sites are increasingly recognised as pathologically significant and independent of its blood-pressure effects. In the vasculature, aldosterone promotes endothelial dysfunction, Oxidative Stress, and inflammation. In the heart, it drives myocardial Fibrosis, hypertrophy, and remodelling β explaining why mineralocorticoid receptor antagonists (spironolactone, eplerenone) reduce mortality in heart failure beyond what blood pressure reduction alone would predict. In macrophages, aldosterone promotes a pro-inflammatory M1 phenotype and increases Oxidative Stress via NADPH oxidase activation. In adipose tissue, aldosterone impairs adipocyte differentiation and promotes inflammation. The mineralocorticoid receptor is noteworthy because it has equal affinity for Cortisol and aldosterone, and since cortisol circulates at 100-1000 fold higher concentrations, cells that should respond to aldosterone contain the enzyme 11-beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2), which converts cortisol to the inactive cortisone, preventing cortisol from activating the MR. When this enzyme is overwhelmed β by excessive cortisol (as in Cushing's syndrome) or inhibited by liquorice (glycyrrhizic acid) β cortisol activates the MR, causing sodium retention, hypertension, and hypokalaemia that mimics hyperaldosteronism.
One of the most clinically significant insights in RAAS biology is the recognition that adipose tissue β particularly visceral fat β constitutes an independent, local RAAS. Adipocytes express angiotensinogen (the RAAS precursor), renin, ACE, AT1 receptors, and mineralocorticoid receptors, creating a complete local RAAS circuit within fat tissue. Visceral adipose tissue produces significant amounts of angiotensinogen β in some obese individuals, adipose-derived angiotensinogen may contribute up to 30% of circulating levels, rivalling hepatic production. This means that obesity directly amplifies systemic RAAS activity regardless of renal perfusion or sodium status, providing a clear molecular mechanism for the well-established association between visceral obesity, hypertension, and chronic low-grade inflammation.
The adipose RAAS creates a vicious cycle: angiotensin II acting on AT1 receptors in adipocytes impairs adipocyte differentiation (producing large, dysfunctional, insulin-resistant adipocytes), promotes adipose inflammation (macrophage infiltration, crown-like structures), and reduces Adiponectin production. These effects worsen insulin resistance, promote further fat accumulation (particularly visceral), and increase angiotensinogen production β a self-amplifying loop that links the RAAS to the metabolic syndrome. The adipose RAAS also helps explain why weight loss β even modest reductions of 5-10% β produces disproportionate improvements in blood pressure: reducing adipose angiotensinogen production breaks the amplification cycle.
SARS-CoV-2 binds to ACE2 as its cellular entry receptor, using the spike protein's receptor-binding domain to engage ACE2 on the cell surface, followed by priming by transmembrane serine protease 2 (TMPRSS2). Viral entry leads to ACE2 internalisation, shedding, and downregulation, effectively removing the counter-regulatory brake on the RAAS. The result is unopposed angiotensin II signaling β vasoconstriction, Oxidative Stress, NF-kB-driven inflammation, enhanced Cytokines production, endothelial damage, and procoagulant effects. This "RAAS imbalance" hypothesis helps explain many features of severe COVID-19: the acute respiratory distress syndrome (Ang II promotes pulmonary oedema and fibrosis), the endotheliitis and thrombotic complications (Ang II activates endothelial cells and promotes coagulation), the cardiovascular complications (myocarditis, arrhythmias), and the acute kidney injury (loss of renal ACE2 protection). Elevated plasma angiotensin II levels have been documented in severe COVID-19 patients and correlate with viral load and disease severity. The tissue expression pattern of ACE2 β lungs, heart, kidneys, intestines, endothelium β maps precisely onto the target organs of COVID-19. This connection between RAAS biology and pandemic pathophysiology represents one of the most vivid examples of how understanding fundamental physiological systems illuminates disease mechanisms.
ACE inhibitors (enalapril, ramipril, lisinopril) and angiotensin receptor blockers (ARBs: losartan, valsartan, candesartan) are first-line antihypertensives that do far more than lower blood pressure. By reducing angiotensin II signaling (ACE inhibitors reduce its production; ARBs block its receptor), these drugs decrease NF-ΞΊB activation, reduce Oxidative Stress, improve endothelial function, decrease myocardial fibrosis, slow renal fibrosis, and improve insulin resistance. This explains their proven benefits in heart failure (mortality reduction), post-myocardial infarction (ventricular remodelling prevention), diabetic nephropathy (proteinuria reduction and renal protection beyond BP lowering), and why they are preferred antihypertensives in patients with metabolic syndrome or diabetes (metabolically neutral or beneficial, unlike older antihypertensives). The anti-inflammatory effects of RAAS blockade are now considered a significant contributor to their cardiovascular benefit, not merely a secondary curiosity.
The RAAS-metabolic connection runs in both directions. RAAS activation worsens insulin resistance through angiotensin II-mediated oxidative stress (which impairs Insulin receptor signaling), aldosterone-mediated potassium depletion (potassium is required for adequate insulin secretion from beta cells), and adipose tissue dysfunction. Conversely, Insulin stimulates angiotensinogen production and enhances AT1 receptor expression, while insulin resistance may impair the vasodilatory component of insulin signaling while preserving its RAAS-stimulatory effects. ACE inhibitors and ARBs have been shown to reduce the incidence of new-onset diabetes by approximately 20-25% compared to other antihypertensives, providing clinical evidence for this metabolic connection.
The cPNI approach to RAAS dysregulation extends far beyond pharmacology. Weight loss β particularly visceral fat reduction through Intermittent fasting, physical activity, and anti-inflammatory nutrition β directly reduces adipose angiotensinogen production. Exercise improves the ACE/ACE2 balance in favour of the counter-regulatory arm. Sodium reduction (to ~5-6g/day) decreases RAAS activation. Potassium-rich diets support aldosterone balance. Stress management and vagal tone enhancement reduce sympathetic input to renin release. Omega-3 fatty acids, vitamin D, and polyphenol-rich foods have all shown effects on RAAS components in human studies. The cPNI perspective recognises that RAAS dysregulation is rarely an isolated hemodynamic problem β it is embedded in a web of inflammatory, metabolic, and neuroendocrine dysfunction that requires systems-level intervention.